Phase I-IIa, national, multicenter, clinical trial to evaluate the safety and preliminary efficacy of CAR-T CD19 therapy in patients with refractory lupus nephritis.
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Sponsor type
Laboratory/Research/Testing facility
Therapeutic area
Immune System Diseases
Decision date
11/06/2026
Enrollment target
10
Sites
Spain
Condition studied
Refractory Lupus Nephritis
Investigational medicinal product(s)
TranspoCART19
Eligibility
Age group
18-64 years
Sex
Female, Male
Primary endpoint
To evaluate the safety and tolerability of CD19 CAR‑T cell therapy (TranspoCART19) in patients with refractory lupus nephritis during the early post‑infusion period (Day 0–28; extended to Day +42 in cases of prolonged cytopenias)
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.